Latest Biotech News

The FDA has granted accelerated approval to Regeneron’s Otarmeni (lunsotogene parvec-cwha), positioning it as the first gene therapy designed to restore neurosensory function to normal levels in...

Moderna began early-stage work on a hantavirus vaccine, according to reports that sparked a notable investor reaction. The Boston Globe and other outlets described the program as still in its...

Researchers at the Medical University of South Carolina (MUSC) reported that the asthma medication formoterol may reverse fatty liver disease biology, including metabolic dysfunction-associated...

10x Genomics filed a lawsuit against Element Biosciences, alleging that Element’s Aviti24 multiomic analysis platform infringes multiple spatial technology patents licensed from Harvard...

Tr1X is advancing an off-the-shelf type 1 regulatory T cell platform after raising attention for its approach to inducing long-term immune tolerance. The San Diego biotech’s lead program, built...

Odyssey Therapeutics raised $304 million through an IPO and concurrent private placement, positioning the company to advance immunology programs tied to its lead ulcerative colitis asset, OD-001....

Guardant Health reported Q1 2026 revenue growth of 48% year over year, lifting its full-year guidance after strong performance in oncology and screening. The company posted $301.7 million in Q1...

Twist Bioscience and LenioBio announced a partnership aimed at accelerating AI-guided protein design using real-world protein molecules. The collaboration focuses on enabling rapid data generation...

Mobia Medical began trading on Nasdaq under ticker MOBI after completing an IPO priced at $15 per share, raising about $150 million. The company sold 10 million shares at the midpoint of its...

Seoul National University researchers developed a next-generation CRISPR biocontainment approach designed to control engineered bacterial survival without DNA cleavage. The work, published in...

Regeneron’s Otarmeni (lunsotogene parvec-cwha) won FDA accelerated approval as the first in vivo gene therapy for OTOF-related severe-to-profound sensorineural hearing loss. The FDA based its...

Moderna’s reported early-stage hantavirus vaccine work triggered investor attention after reports surfaced that the company has started research on a potential jab. The project is described as in...

Odyssey Therapeutics priced an upsized IPO and concurrent private placement to raise $304 million as it advances its lead Phase II program for ulcerative colitis and plans further development...

Regulatory timelines shifted for Alzheimer’s therapy lecanemab (Leqembi) as the FDA delayed a decision on the company’s proposed subcutaneous route. Biogen and Eisai said the decision date was...

Guardant Health beat expectations with a Q1 2026 revenue surge, raised full-year guidance, and pointed to continued momentum in oncology and screening. The company reported Q1 revenue of $301.7...

Mobia Medical began trading on Nasdaq after pricing its IPO at $15 per share, raising about $150 million. The company sold 10 million shares at the midpoint of its $14–$16 target range and ended...

10x Genomics forecast dimmed spatial biology sales as it rolls out its Atera in situ spatial platform and reiterated full-year guidance. In a business update tied to the platform launch, the...

10x Genomics sued Element Biosciences over alleged patent infringement involving Element’s Aviti24 multiomic analysis platform. The complaint, filed in the District of Delaware, alleges Aviti24...

Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), an antibody-drug conjugate targeting MUC16 and NaPi2b. The IND clearance enables initiation of a Phase I trial expected to...

Amplified Sciences initiated patient enrollment for PanAMP, a multicenter clinical utility study designed to evaluate how its PanCystPro assay influences clinical decision-making for early...